Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.23.00033 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Andrew J Davies und 22 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK.
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression–based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
- Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals, Leeds, United Kingdom.
- Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom.
- Cantonal Hospital Aarau, Aarau, Switzerland.
- Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
ORCID-Profile: Andrew J Davies, Sam Wilding, Christoph Mamot, Urban Novak, Richard Stephens, Chulin Sha, Reuben Tooze, Gareth Griffiths, Anna Schuh, David R Westhead, Peter W M Johnson
Förderung
- Cancer Research UK
Zitieren
APA
Davies, A. J., Barrans, S., Stanton, L., Caddy, J., Wilding, S., Saunders, G., Mamot, C., Novak, U., McMillan, A., Fields, P., Collins, G. P., Stephens, R., Cucco, F., Sha, C., van Hoppe, M., Tooze, R., Davies, J. R., Griffiths, G., Schuh, A., …, & Johnson, P. W. M. (2023). Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00033
Vancouver
Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00033
BibTeX
@article{Davies2023,
author = {Davies, Andrew J and Barrans, Sharon and Stanton, Louise and Caddy, Josh and Wilding, Sam and Saunders, Geoff and Mamot, Christoph and Novak, Urban and McMillan, Andrew and Fields, Paul and Collins, Graham P and Stephens, Richard and Cucco, Francesco and Sha, Chulin and van Hoppe, Moniek and Tooze, Reuben and Davies, John R and Griffiths, Gareth and Schuh, Anna and Burton, Catherine and Westhead, David R and Du, Ming-Qing and Johnson, Peter W M},
title = {Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.23.00033}
}
EUVIMED